ProQR Therapeutics N.V.
NASDAQ:PRQRBiotechnology
+$0.21 today
- Market cap
- $155.23M
- Beta
- 0.06
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.43
Volume 0.88M
Average 0.62M
PRQR Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
ProQR Therapeutics N.V.NASDAQ: PRQR
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of €12.02M fell 2.4% year over year, behind the +12.6% change in trailing-twelve-month research & development. Sequentially, it rose 22.3% from the prior quarter. Over 3 fiscal years it compounded at -7.1% a year.
Context
- Research & development amounted to 266.5% of revenue in FY2025, up 74.2 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -2.4% toward the trailing-twelve-month pace of +12.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
EUR · from the income statement
- Latest · FY2025
- 40.72M EUR
- Year-over-year change
- +12.0%
- 4-year CAGR
- -0.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 40.72M | +12.0% |
| FY2024 | 2024-12-31 | 36.36M | +44.6% |
| FY2023 | 2023-12-31 | 25.15M | -50.6% |
| FY2022 | 2022-12-31 | 50.87M | +20.5% |
| FY2021 | 2021-12-31 | 42.22M | — |
Research & Development vs competitors
How PRQR compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +12.6% is the 5th highest of 11, against a peer median of -0.8%.
- Research & development amounts to 329.9% of revenue for PRQR, versus a peer median of 717.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $143.25M USD | +11.2% | +28.8% | 2496.5% | |
| LTM Mar 2026 | $129.09M USD | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $101.99M USD | +14.6% | +8.4% | 46.8% | |
| LTM Mar 2026 | $98.25M USD | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | $92.92M USD | +60.8% | +57.0% | — | |
| LTM Mar 2026 | $66.19M USD | -62.3% | -19.9% | 171.1% | |
| FY2025 | A$61.41M AUD | +47.8% | +25.1% | 1217.6% | |
ZURAZura Bio Limited | LTM Mar 2026 | $46.35M USD | +48.2% | +21.1% | — |
| LTM Mar 2026 | €44.34M EUR | +12.6% | -7.1% | 329.9% | |
| LTM Mar 2026 | $19.19M USD | -29.2% | -8.6% | — | |
| LTM Mar 2026 | $18.13M USD | -12.8% | -16.7% | 3625.8% | |
| Peer median (excluding PRQR) | — | -0.8% | -0.1% | 717.1% | |
Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.34M | 3.59M | 6.51M | 18.91M | 15.28M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.6M |
| Gross Profit | 1.34M | 3.59M | 6.51M | 18.91M | 12.68M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 83.0% |
| Research & Development | 42.22M | 50.87M | 25.15M | 36.36M | 40.72M |
| Selling, General & Admin | 17.37M | 18.65M | 16.24M | 13.66M | 14.12M |
| Operating Expenses | 58.55M | 68.75M | 38.37M | 49.38M | 54.84M |
| Depreciation & Amortization | 2.33M | 2.52M | 2.51M | 2.76M | 2.6M |
| EBITDA | (54.95M) | (56.46M) | (24.1M) | (24.12M) | (37.04M) |
| EBITDA Margin | -4116.0% | -1571.0% | -369.9% | -127.6% | -242.4% |
| Operating Income | (57.21M) | (65.16M) | (31.86M) | (30.47M) | (42.15M) |
| Operating Margin | -4285.4% | -1813.0% | -489.1% | -161.2% | -275.9% |
| Interest Income | 5K | 106K | 2.59M | 3.25M | 2.24M |
| Interest Expense | 3.41M | 5.13M | 1.2M | 1.08M | 866.4K |
| Other Income / Expenses | (3.47M) | 1.05M | 4.05M | 2.51M | 1.65M |
| Income Before Tax | (60.68M) | (64.11M) | (27.81M) | (27.96M) | (40.5M) |
| Pre-Tax Margin | -4545.5% | -1783.8% | -427.0% | -147.9% | -265.1% |
| Income Tax Expense | 117K | 96K | (78K) | (197K) | 18.25K |
| Net Income | (60.74M) | (64.42M) | (28.12M) | (27.76M) | (40.52M) |
| Net Margin | -4549.8% | -1792.5% | -431.7% | -146.9% | -265.2% |
| EPS (Basic) | (0.96) | (0.91) | (0.35) | (0.34) | (0.38) |
| EPS (Diluted) | (0.96) | (0.91) | (0.35) | (0.34) | (0.38) |
| Weighted Avg Shares | 64.18M | 71.64M | 81.01M | 81.67M | 105.33M |
| Weighted Avg Shares (Diluted) | 64.18M | 71.64M | 81.01M | 81.67M | 105.33M |
ProQR Therapeutics N.V.
NASDAQ:PRQR
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.